CHUNLI MEDICAL (01858) rose over 9% intraday, extending its post-earnings rally to nearly 25%. At the time of writing, the stock was up 7.87% to HK$20.42, with a turnover of HK$125 million.

The company recently reported strong financial results, with revenue for the first three quarters reaching RMB756 million, a 48.75% year-on-year increase. Net profit surged 213.21% to RMB192 million. In the third quarter alone, revenue grew 109.51% to RMB268 million, while net profit attributable to shareholders turned around to RMB77.06 million from a loss in the same period last year.

HTSC attributed the robust third-quarter performance to CHUNLI MEDICAL's steady expansion in international markets, continuous growth in export revenue, and increased sales of centralized procurement products. The brokerage remains optimistic about sustained rapid growth in overseas income and maintains its "Buy" rating on the stock.